CN114728180A - 使用抗FcRn抗体治疗温性自身免疫性溶血性贫血的方法 - Google Patents

使用抗FcRn抗体治疗温性自身免疫性溶血性贫血的方法 Download PDF

Info

Publication number
CN114728180A
CN114728180A CN202080080573.3A CN202080080573A CN114728180A CN 114728180 A CN114728180 A CN 114728180A CN 202080080573 A CN202080080573 A CN 202080080573A CN 114728180 A CN114728180 A CN 114728180A
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080080573.3A
Other languages
English (en)
Chinese (zh)
Inventor
克莉丝汀·莫雷尔·寇可利
乔纳森·安德鲁·克卢夫特
威廉·托马斯·西蒙兹三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yimu Nuowan Science Co ltd
Original Assignee
Yimu Nuowan Science Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yimu Nuowan Science Co ltd filed Critical Yimu Nuowan Science Co ltd
Publication of CN114728180A publication Critical patent/CN114728180A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080080573.3A 2019-11-19 2020-11-18 使用抗FcRn抗体治疗温性自身免疫性溶血性贫血的方法 Pending CN114728180A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
US62/937,395 2019-11-19
PCT/US2020/061028 WO2021101975A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies

Publications (1)

Publication Number Publication Date
CN114728180A true CN114728180A (zh) 2022-07-08

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080573.3A Pending CN114728180A (zh) 2019-11-19 2020-11-18 使用抗FcRn抗体治疗温性自身免疫性溶血性贫血的方法

Country Status (11)

Country Link
US (1) US20230049011A1 (https=)
EP (1) EP4061486A1 (https=)
JP (1) JP7722991B2 (https=)
KR (1) KR20220100880A (https=)
CN (1) CN114728180A (https=)
AU (1) AU2020387399A1 (https=)
CA (1) CA3157797A1 (https=)
IL (1) IL292889A (https=)
MX (1) MX2022005862A (https=)
TW (1) TW202132346A (https=)
WO (1) WO2021101975A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250136699A1 (en) * 2021-08-13 2025-05-01 Jiangsu Biojetay Biotechnology Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
US20260078188A1 (en) * 2022-09-06 2026-03-19 Immunovant Sciences Gmbh Methods of treating graves’ disease using anti-fcrn antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459215A (zh) * 2014-04-30 2017-02-22 韩诺生物制药株式会社 治疗自身免疫疾病的结合fcrn的抗体
US20170210805A1 (en) * 2014-04-30 2017-07-27 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
WO2018023136A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
CN108025066A (zh) * 2015-05-12 2018-05-11 Synt免疫公司 人源化亲和力成熟的抗FcRn抗体
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250052465A (ko) * 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459215A (zh) * 2014-04-30 2017-02-22 韩诺生物制药株式会社 治疗自身免疫疾病的结合fcrn的抗体
US20170210805A1 (en) * 2014-04-30 2017-07-27 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
CN108025066A (zh) * 2015-05-12 2018-05-11 Synt免疫公司 人源化亲和力成熟的抗FcRn抗体
WO2018023136A1 (en) * 2016-07-29 2018-02-01 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2019160979A1 (en) * 2018-02-13 2019-08-22 The Brigham And Women's Hospital, Inc. Therapeutic fcrn-based bispecific monoclonal antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAURENCE BLUMBERG: "SYNT001: A Humanized IgG4 Monoclonal Antibody That Disruptsthe Interaction of FcRn and IgG for the Treatment of IgG-Mediated Autoimmune Diseases", BLOOD, 7 December 2017 (2017-12-07), pages 1 - 2 *
SEOKJUN LEE: "Hanall biopharma 预计年内有4个新药技术费流入", pages 1 - 3, Retrieved from the Internet <URL:https://www.dailypharm.com/Users/News/NewsView.html?ID=256420> *

Also Published As

Publication number Publication date
IL292889A (en) 2022-07-01
JP7722991B2 (ja) 2025-08-13
US20230049011A1 (en) 2023-02-16
EP4061486A1 (en) 2022-09-28
WO2021101975A1 (en) 2021-05-27
JP2023502398A (ja) 2023-01-24
AU2020387399A1 (en) 2022-05-19
MX2022005862A (es) 2022-06-23
TW202132346A (zh) 2021-09-01
CA3157797A1 (en) 2021-05-27
KR20220100880A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
CN113423426B (zh) 使用抗FcRn抗体治疗格雷夫斯眼病的方法
US20240092913A1 (en) Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) Antibody binding to FcRn for treating autoimmune diseases
CN114728180A (zh) 使用抗FcRn抗体治疗温性自身免疫性溶血性贫血的方法
HK40068854A (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
CN119768431A (zh) Igf1r抗体
HK40058301A (en) Methods of treating graves&#39; ophthalmopathy using anti-fcrn antibodies
HK40058301B (zh) 使用抗fcrn抗体治疗格雷夫斯眼病的方法
HK40124168A (zh) 使用抗fcrn抗体治疗格雷夫斯病的方法
HK1230217B (zh) 治疗自身免疫疾病的结合fcrn的抗体
HK1230217A1 (en) Antibody binding to fcrn for treating autoimmune diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068854

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220708

WD01 Invention patent application deemed withdrawn after publication